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SA100A8, SA100A9, and SA100A12 are members of the myeloid-related protein class. SA100A8 and SA100A9, also known as
MRP-8 and MRP-14, respectively, are intracellular Ca2+-binding proteins produced mainly by neutrophils and monocytes where
they exist as a heterodimeric complex in the cytosol. The MRP-8/-14 complex has been shown to promote chronic inﬂammation
associated with rheumatoid arthritis (RA). In that regard, MRP-8 and MRP-14 regulate the inﬂammatory response through their
capacity to recruit neutrophils and monocytes to target tissues resulting in attachment to endothelium. MRPs also activate the
signal transduction pathway principally involving the stress-activated/mitogen-activated protein kinases. MRP-8/MRP-14 also
increased nitric oxide synthesis. Most recently, the MRP-8/MRP-14 complex was shown to be a novel ligand for the toll-like
receptors (TLRs) and TLR-4, in particular. Engagement of TLRs by the MRP-8/-14 complex may be particularly important
for activating antigen-presenting dendritic cells which regulate critical autoimmune responses that promote chronic synovitis
characteristic of RA.
1.Introduction
The myeloid-related protein (MRP) family of proteins in-
clude MRP-8, also known as S100A8, MRP-14, also known
as SA100A9, and S100A12 [1]. MRP-8 and MRP-14 are
intracellular Ca2+-binding proteins that are produced by
a variety of myeloid cells. MRP-8 and MRP-14 exist as a
heterodimeric complex in the cytosol of polymorphonuclear
leukocytes and monocytes [2, 3].
2. The MRP Complex and Inﬂammation
MRPs have been implicated as important contributors to
inﬂammation in general, and to the overall inﬂammatory
response associated with autoimmune disorders such as
rheumatoid arthritis (RA) [4, 5]. The MRP-8/14 complex,
in particular, has been proposed to play a critical role in
regulating several of the inﬂammatory responses associated
with RA because both MRP-8 and MRP-14 can promote
chronic inﬂammation and act to recruit neutrophils and
monocytes to inﬂamed tissue by enhancing their migration,
retention, and attachment to the endothelium [6]. In this
regard, the best evidence for the fundamental role played
by the MRPs in inﬂammation [7, 8]c a nb eg l e a n e df r o m
the results of experimental studies which demonstrated
that exogenously added MRP-8/14 was capable of directly
inducing macrophage recruitment to inﬂamed tissues which
was also accompanied by increased levels of nitric oxide
(NO) [8, 9].
3. The MRP Complex, NO, and
Signal Transduction
NO has been shown to be an important soluble mediator of
inﬂammatory responses in adult RA via the upregulation of
inducible nitric oxide synthase (iNOS) as a result of nuclear
factor κB( N F - κB) activation [10]. In addition, NO has been
shown to be a potent inducer of apoptosis in cultured articu-
lar chondrocytes [11, 12]. Importantly, MRP-8/14-mediated
up-regulation of iNOS gene expression by macrophages in
vitrowasalsoshowntoalsobeaccompaniedbytheactivation
(i.e., phosphorylation) of multiple protein kinase-mediated
signal transduction pathways, including those involving c-
Jun-N-amino-terminal kinase (JNK), extracellular-regulated
kinase 1/2 (ERK1/2), and Janus kinase/signal transducers2 International Journal of Inﬂammation
and activators of transcription (JAK/STAT) as well as ac-
tivation of NF-κB. Interestingly, JAK/STAT was found to
be preferentially activated by interferon-γ (IFN-γ) rather
than by MRP-8/14 [4]. However, the activation of multiple
downstream signal transduction pathways by NO, IFN-γ,
MRP-8/14, and other proinﬂammatory cytokines, namely,
tumornecrosisfactor-α(TNF-α),IL-6,IL-8,IL-12/23,IL-18,
and so forth [13] has profound implications for any future
therapeutic interventions for RA [14–17] because it would
be unlikely that suppression or inhibition of any one of these
signalingpathwayswouldamelioratetheinﬂammationofRA
or reduce articular cartilage destruction and/or subchondral
bone erosions characteristic of RA [18].
4. TissueLocalizationandCirculating
MRP Complex in RA
MRP antigens were found to reside only in the macrophage
subtype in the synovial membrane of RA synovial tissue [4].
Importantly, the relevance of MRP antigen localization to
synovial joint cartilage destruction and subchondral bone
erosion in RA was also supported by the ﬁnding that MRP
antigens were localized only to those cells that were adjacent
to the cartilage-pannus junction and only in RA patients
withclinicallyactivedisease[4].Theseﬁndingssuggestedthe
possibilitythatsuppressionofMRPgeneexpressionmightbe
a suitable novel target for therapeutic intervention to inhibit
the progression of juvenile chronic arthritis [19, 20] and/or
adult RA [8].
Importantly, in RA patients, the serum levels of MRP-
8/14 and SA100A12 correlated with one another [5]. More-
over, serum levels of MRP-8/14 and S100A12 in 138 patients
with RA were substantially elevated compared to 44 healthy
controls. The S100A9 serum levels were detected using an
anti-MRP-14 antibody that not only measured MRP-14 but
also detected MRP-14 in its complex with MRP-8. These
levels were about 100-fold lower than those reported in
other studies [21, 22], and the diﬀerences between the
results of these two studies [5, 21]c o u l db ea c c o u n t e df o r
on the basis of the speciﬁcity of the anticalprotectin (an
antibody generated against the MRP-8/14 complex) that
was previously employed [21, 22]. Taken together, these
results indicated that elevated levels of circulating serum
MRP antigens in RA patients were coordinately increased.
Thus, the level of circulating MRP-8/14/SA100A12 could
potentially be employed as a biomarker to track the patho-
logic and radiographic progression of RA as well as clinical
responses and other objective measurements to approved RA
therapeutic DMARDs and/or biologic agents.
In addition to the above, elevated levels of these MRP
antigens were also shown to signiﬁcantly contribute to
vascular injury and thus to the peripheral end-organ damage
in adult RA [5] which both signiﬁcantly contribute to the
numerous comorbid components of RA disease activity.
The elevated levels of peripheral and organ-related MRP
antigens may also be associated with precocious atheroma
formation and the accelerated development of atherosclero-
sis which has been found to correlate with vascular injury
and the later development of coronary artery disease [23,
24] which is often seen as a signiﬁcant comorbidity in
RA patients with clinically active disease [25–27]. Interest-
ingly, carotid intima media thickness (cIMT), a marker of
preclinical atherosclerosis, and ﬂow-mediated dilatation
(FMD) of the brachial artery, a marker of endothelial dys-
function, were assessed in 79 patients with early RA and in
44 age-matched and sex-matched controls [28]. Importantly,
the FMD and cIMT at baseline were not signiﬁcantly
diﬀerent between the two groups. Thus, the results of
this study indicated that although preclinical evidence of
atherosclerosis was often associated with early RA, there was
also a strong indication that early therapeutic intervention
in RA (perhaps by targeting MRP-8/14 antigens) could
establish a means to signiﬁcantly reduce the progression of
atherosclerosis in these RA patients.
Importantly, in systemic-onset juvenile RA (JRA),
a strong and positive correlative relationship was found
between the level of MRP-8/14 in the peripheral circulation
and the level of another proinﬂammatory cytokine, germane
to RA disease activity and progression, namely, interleukin-
1β (IL-1β), [29]. This result suggested that in JRA, the
MRP-8/14 complex in conjunction with IL-1β constituted
a novel positive feedback pathway that could account for
the robustness of macrophage activation in this arthritic
disorder of childhood.
5. What Is the Evidence That the MRPs Help
DriveRADisease Progression?
5.1. Toll-Like Receptors (TLRs). TLR-mediated signaling is
a crucial component in driving both innate and adaptive
immune activation [30]. Recently, the MRP-8/14 complex
was shown to be a novel ligand for the TLR pathway
and for TLR-4, in particular [31, 32]. Thus, in a fashion
similartoLPS,aknownactivatorofTLR-mediatedsignaling,
MRP-8 induced the hyperphosphorylation of IL-1 receptor-
associated kinase-1 in human IFN-γ-primed monocytes that
was also characterized by elevated levels of TNF-α,I L -
1β,a n dI L - 1 2[ 32]. In addition, LPS and MRP-8 were
used to determine the extent to which these responses
occurred in murine phagocytes without a functional TLR-
4 complex. Thus, compared to their wild-type counterparts,
TLR-4 mutant mice demonstrated a similar lack of response
to both LPS and MRP-8, but in contrast to wild-type
mice, stimulation of TLR-9, -8, or -7 with cpG and R848,
respectively, revealed no diﬀerences in response. These data
indicated that MRP-8 was an endogenous ligand of TLR-4
and that the MRP-8/-14 complex stimulation of TLR-4 was a
mechanism for increasing the eﬀect of LPS stimulated by the
MRP-8/14 complex. In this regard, the TLR pathway having
been engaged by the MRP-8/14 complex may be particularly
important for activating antigen-presenting dendritic cells
which regulate, in part, several of the autoinﬂammatory and
autoimmuneresponses,whichinthecontextofRApromotes
the chronic state of synovitis [32].International Journal of Inﬂammation 3
5.2. Chemokines and Adhesion Molecules. The elevated pro-
duction of chemokines and adhesion molecules are also cru-
cial to the pathogenesis of experimentally-induced murine
arthritis [33]a n dh u m a nR A[ 34]. Thus, TNF-α not only
promotes the inﬂammatory responses associated with RA
[34] but also enhances the migration of neutrophils towards
CCL3, known as macrophage inhibitory protein-1α (MIP-
1α), via its capacity to interact with CCR5 [34, 35].
The MIP-1α/CCR5 response also appears to be a conse-
quence of TNF-α-induced up-regulation of CD11b/CD18,
also known as macrophage-activating complex-1, (Mac-
1), which was found on the surface of neutrophils. In
this regard, Newton and Hogg [36] found that MRP-14
activated Mac-1 on the surface of neutrophils, whereas
Rouleauet al. [37] showed that SA100A12 induced enhanced
neutrophil migration and adhesion as well as release from
mouse bone marrow at concentrations comparable to those
levels of SA100A12 found in the plasma of patients with
inﬂammatory arthritis. Therefore, it was noteworthy that
BIIL3, a long-acting leukotriene B4 (LTB4) receptor antag-
onist, inhibited LTB4-induced Mac-1 expression in patients
with RA [38].
5.3. MRP Levels in Response to Antirheumatic Disease Ther-
apies. Although a rapid lowering of MRP levels in syn-
ovial tissue sublining macrophages was associated with
the positive clinical response of RA patients to anti-TNF-
α therapy [39, 40], could MRP levels be employed as
a sensitive biomarker for distinguishing between eﬀective
and ineﬀective drug interventions? In this regard, the data
from 2 randomized, controlled RA clinical trials were re-
examined in which experimental therapies designed to
neutralize either monocyte chemotactic protein-1 (MCP-
1) activity or the interaction between C5a and its receptor
C5aR were assessed with each of these strategies failing to
show clinical eﬃcacy. In this analysis, Wijbrandts et al. [41]
combinedthedatafromthese2studieswithclinicalresponse
and CD68 data from other RA clinical trials in which
combinations of DMARDs and biological agents resulted
in a positive clinical response. The “standardized response
mean” (SRM) was employed as the outcomes measure. The
results of this study showed a strong relationship between
lower disease activity score-28 (DAS-28) levels (a standard
for measuring clinical response in RA clinical trials) and
the number of CD68-positive sublining macrophages (SRM,
>0.8). This result indicated that the number of CD68-
positive sublining macrophages which had been previously
shown to be positive for MRP [39]w a sas e n s i t i v eb i o m a r k e r
to measure clinical responses to eﬀective therapies in RA
clinical trials, but not for the interventions which were inef-
fective (anti-MCP-1, SRM, 0.19; anti-C5aR, SRM, -0.071).
Furthermore, the diﬀerence in the weighted mean of the
SRMbetweenclinicallyeﬀectiveandineﬀectiveinterventions
was signiﬁcant for both DAS-28 and the number of CD68
sublining macrophages which indicated that the weighted
mean of the SRM could be used to detect diﬀerences
between eﬀective and ineﬀective interventions as well as
placebo eﬀects [41]. It should be noted that Haringman et al.
[42] had also previously shown a similar strong correlation
between lowered DAS-28 scores and the number of CD68
subliningmacrophages(Pearsoncorrelation,0.874,P<0.01)
in response to several types of antirheumatic therapies.
Additionally, patients with spondyloarthropathy or adult
RA who responded favorably to the anti-TNF-α monoclonal
antibody inﬂiximab showed a rapid and marked decrease in
the level of MRP-positive macrophages in tissue inﬁltrates,
but not in the total population of resident macrophages [43].
Furthermore, inﬂiximab eﬀectively reduced the soluble form
of MRP-8/14 in the sera of RA patients but had no eﬀect on
the level of the soluble form of CD163 [39].
It has also been important to assess the extent to which
the number of MRP-positive macrophages in RA patients
in response to anti-TNF-α therapy correlated with changes
in other biomarkers of inﬂammation. To address this issue,
van Kuijk et al. [44] showed that lower DAS-28 scores could
be achieved in patients with psoriatic arthritis receiving the
anti-TNF-α monoclonal antibody, adalimumabcomparedto
placebo. In this analysis of psoriatic arthritis, patients who
favorably responded to adalimumab signiﬁcantly reduced
levels of matrix metalloproteinase-3 (MMP-3) and MMP-13,
and a trend towards lower levels of von Willerbrand factor,
IL-1 and IL-6, was found. Moreover, clinical improvement in
these psoriatic arthritis patients in response to adalimumab
was strongly correlated with reduced numbers of CD3/CD4-
positive T cells, and MRP-8-positive macrophages.
Taken together, these results suggested that suppres-
sion of Mac-1 expression or blockade of TNF-α-mediated
cellular signaling by anti-TNF-α therapies may result in
the inhibition of migration and adhesion of neutrophils
and macrophages into inﬂamed tissue, in part, by regu-
lating MRP complex-mediated migration and adhesion of
these inﬂammatory cells to speciﬁc end-organ sites. Thus,
measurements of MRP-8 was one of several biomarkers,
including MMP-3, MMP-13, and CD68 (a marker for
macrophages expressing MRP-8) but not CD163 (a marker
for resident tissue macrophages) in the sublining of synovial
tissue as well as neutrophils. In eﬀect, changes in the levels
of these biomarkers were shown to be useful in making
predictions regarding the clinical responses of patients with
spondyloarthropathy to inﬂiximab [45]b u tw e r es o m e w h a t
in conﬂict with the results reported by De Rycke et al. [43]
who determined that anti-TNF-α therapy appeared to alter
the expression of cell-speciﬁc CD163 as well as CD68.
5.4. Regulation of Signal Transduction Pathways: Cell Survival
and Apoptosis. Signal transduction pathways that are acti-
vatedinRAinresponsetoelevatedlevelsofproinﬂammatory
cytokines [13, 18, 46] include JNK, ERK 1/2, p38 kinase,
and JAK/STAT which may all be diﬀerentially activated
by the MRP complex [4] .I nt h a tr e g a r d ,M o r e le ta l .
[47]recentlydemonstratedthatJNKactivitywasessentialfor
regulating the phosphorylation of Mcl-1 (a member of the
Bcl2-related protein family) by glycogen synthase kinase 3
(GSK3). Importantly, activation of Mcl-1 may also be re-
sponsible for controlling the survival and/or apoptosis
of neutrophils, macrophages, and other cells essential in4 International Journal of Inﬂammation
activating the inﬂammation cascade in RA. Thus, in future
studies, it will be of interest to determine the extent to which
the MRP protein complex regulates the activation of Mcl-1
and GSK3.
Finally, MRP-14 was shown to be a potent activator of
p38 kinase-dependent functional responses in intact human
neutrophils that included the regulation of neutrophil sur-
vival and apoptosis [48]. Thus, suppression of MRP-14 ac-
tivity may be important in the context of developing novel
therapeutic strategies for regulating neutrophil-associated
survival in RA via suppression of MRP complex-mediated
signaling.
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